Inovio BioMedical

Latest Headlines

Latest Headlines

PATH, Inovio zero in on DNA malaria vaccine

Expanding an already solid partnership, PATH Malaria Vaccine Initiative and Inovio Pharmaceuticals will work together to advance malaria vaccine development and new vaccination delivery technologies.

Inovio makes steps toward a universal flu vax

Inovio Pharmaceuticals thinks it is a step closer to the prize with a universal avian flu vax that has triggered protective responses against 6 h5N1 virus in one go in a Phase I clinical trial.

In the clinic, Inovio's HIV vaccine treats as well as prevents

Inovio's HIV vaccine has triggered significant immune responses against a number of HIV antigens in a therapeutic clinical trial presented at the Vaccine World Summit 2012 in Hyderabad, India.

Inovio vaccine targets head and neck HPV subtypes

Inovio has created a SynCon DNA vaccine against HPV6 and HPV11, which, in a preclinical trial published in Human Vaccines & Immunotherapeutics, triggered a strong immune response in mice.

Confident Inovio chief pushes ahead on universal flu vaccine

Inovio Pharmaceuticals ' irrepressible Joseph Kim gets the spotlight at U.S. News & World Report, which highlights the company's work on a universal flu vaccine and the CEO's certainty...

Inovio, VGX ink hep B and C vaccine deal

Blue Bell, PA-based Inovio Pharmaceuticals and VGX International will collaborate on the development of Inovio's synthetic vaccines for hepatitis B and hepatitis C. Financial details of the deal were

Inovio posts positive preclinical HIV vax results

Blue Bell, PA-based Inovio Pharmaceuticals has published data from two preclinical HIV trials this week. The results, published in Vaccine and PLoS One respectively, demonstrated the vaccines'

Live from BIO: Transitioning to human models a big obstacle for DNA cancer vaccines

WASHINGTON, D.C.-- A panel at the 2011 BIO International convention explained that the real obstacle comes when the focus turns to humans rather than animal models. As a collaborator of Inovio

Inovio's cervical dysplasia vax shows Ph1 promise

Pennsylvania-based vaccine developer Inovio Pharmaceuticals has released positive Phase I results for its cervical dysplasia and cancer vaccine, VGX-3100. According to Dr. J. Joseph Kim, Inovio's

Inovio, Transgene and ChronTech enter HepC pact

Using a variation of the typical booster shot vaccination process, Inovio Pharmaceuticals, Transgene and ChronTech Pharma have joined together for a Phase I study of a therapeutic hepatitis C
  • 1
  • 2
  • next ›
  • last »